VALEANT PHARMACEUTICALS: Bausch + Lomb Launches LUMIFY, The First And Only OTC Redness Relieving Eye Drop With Low-Dose Brimonidine

Source: Valeant pharmaceuticals

Valeant pharmaceuticals issued the following announcement on May 7.

Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), today announced the launch of LUMIFY™ (brimonidine tartrate ophthalmic solution 0.025%), the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate for the treatment of eye redness.

"With the availability of LUMIFY, consumers now have an innovative, over-the-counter treatment option that can help relieve red, irritated eyes within a minute and offer up to eight hours of redness reduction," said Joseph C. Papa, chairman and CEO, Valeant. "LUMIFY is unlike other redness relievers on the market and will provide consumers a new welcomed alternative."

Eye redness is a common, non-specific issue that affects millions of people. Other redness relievers are commonly associated with the potential side effects of rebound redness and loss of efficacy over time. LUMIFY works by selectively targeting redness and thereby reducing the potential for these side effects.

In clinical trials, LUMIFY eye drops demonstrated 95% improvement at one minute with significant results lasting up to eight hours. A recent in-home-use-study with over 300 participants also resulted in a 95% satisfaction rating for the product.

"LUMIFY eye drops deliver a safe and effective redness relieving OTC option that my patients have been asking for," said Paul Karpecki, O.D., FAAO, director of Corneal Services at Kentucky Eye Institute. "I am excited to introduce these new eye drops into my practice and offer my patients long-lasting symptom relief without the adverse effects commonly associated with other redness relievers."

LUMIFY is available for purchase at major retailers nationwide, including Walgreens, CVS, Rite Aid, Walmart, Target and Amazon. The bottles, available in 2.5 mL and 7.5 mL sizes, have suggested retail prices of $14.99 and $25.99, respectively.

The brimonidine tartrate ophthalmic solution 0.025% product was licensed by Eye Therapies, Inc. to Bausch & Lomb Incorporated or its affiliates.

For more information, please visit

Original source can be found here.

Want to get notified whenever we write about Valeant Pharmaceuticals ?
Next time we write about Valeant Pharmaceuticals, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Valeant Pharmaceuticals 400 Somerset Corporate Blvd Bridgewater, NJ 08807